Last update March 24, 2019
An antineoplastic from the nitrosurea group that acts as an alkylating agent. Indicated topically in the treatment of mycosis fungoides.
Since the last update we have not found published data on its excretion in breastmilk.
The small dose applied, the minimal adverse effects of its topical application (MacArthur, 2017, Zackheim 2003, Zackheim 1985), its rapid systemic elimination and its low oral bioavailability would make interruption of breastfeeding unnecessary.
As it is a medication with minimal but possibly serious adverse effects (Zackheim 1990), it would be advisable to wait 5 hours (5 half lives) before resuming breastfeeding. Meanwhile, express and discard milk from the breast regularly.
It is advisable to avoid application in places that may come into direct contact with the infant, or clean well before the infant can come into contact with the treated area of the skin.
Given the strong evidence that exists regarding the benefits of breastfeeding for the development of babies and the health of mothers, it is advisable to evaluate the risk-benefit of any maternal treatment, including chemotherapy, individually advising each mother who wishes to continue with breastfeeding (Koren 2013).
We do not have alternatives for L01AD01.
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.